protein RIAM that interact with both talin and Rap1. However, some cell types, such as platelets, have very low level of RIAM and mouse models with RIAM KD did not show impaired integrin activation. This lead to further investigations that showed direct contribution of talin-Rap1 interaction into the integrin activation, attributed by Zhu ea (2018) to the talin F0 head domain. However, when the authors of this manuscript introduced the mutation into F0 that disrupts the interaction with Rap1, the activation of integrin was hardly affected (Lagarrigue ea, 2018) , suggesting that F0 may not be the primary mediator of the Rap1-talin connection. This opened again the question of connection between Rap1 and talin in the absence of adaptor molecules. In the submitted manuscript the authors resolved this critical question by reporting a novel interaction between talin F1 and Rap1 that, in combination with the membrane-binding F1-loop, supports Rap1-dependent integrin activation. The manuscript is written clearly and supported by a combination on in vitro and cell data. The authors first demonstrate direct interaction between talin F1 and Rap1, and then use single-residue mutations and domain deletions in A5 cells to relate the interaction to the integrin activation. Several points, however, need to be clarified. 1. The manuscript clearly contradicts the conclusion of Zhu ea (2018) that only F0 in the talin head binds Rap1. In that study, only the effect of F1F2 addition on 15N-Rap1 NMR signals was tested and no significant changes detected. However, the reverse experiment with using 15B-F1F2 was not conducted and no evidence of the correct folding of F1F2 presented, which limits the reliability of the conclusion. At the same time, the effect of Rap1 on the spectrum of 15N-F0 appears to much stronger than on 15N-F1 reported here. Zhu ea (2018) describe extensive broadening and significant shift changes in a number of resonances at 50 mM 15N-F1 to 125 mM of Rap1, while Fig 2C of this manuscript shows much small changes at much larger excess of Rap1 (700mM), and no broadening of signals mentioned. Considering the importance of this evidence of the interaction, the changes in the spectra need to be presented in more detail. (i) Summarise the chemical shift changes as a plot against the residue number and show the mapping of the significant changes on the F1 structure.
(ii) Show the changes of the side-chain Arg signals. Considering the predicted salt-bridges of the complex, large spectral changes are expected in these signals. The R118 signal should be possible to assign using R118E mutant. These data will also provide support for the formation of the salt bridges. 2. The binding constant has been estimated from extremely small shift changes of K89 and D94 (Fig2D & E) , which makes it highly unreliable. The spectra show larger shift changes, that, surprisingly, were not used, such as T96 and unmarked signal in the middle of the spectrum. Considering the small spectral differences, the authors should show the fitting of all the significant shift changes used and report individual Kds in the supplementary, and the largest in the main figure. Signals used in the Kd determination should be labeled on the spectraum. 3. Model of the complex has to be presented to show complementary of the surfaces and formation of salt-bridges. Authors should consider HADDOCK as an independent way of generating the model of the complex based on the chemical shift mapping. 4. Data on the WT needs to be presented in Fig.1D and compared to other fragments. 5. The overall conclusion on the role of F0 is unclear. Considering all the fragments and mutants that have been tested, the authors should be in the position to say whether F0 contributes at all or is redundant in their system. A more informative discussion on this should be included. Minor points 1. Fig1A would be better shown as 3 separate spectra. Authors can consider including spectrum of 15N-Rap1 in the presence of F1-F3, which will further support their arguments. While R35E mutation reduces the affinity significantly, the residual binding might still be significant to cause broadening.
2. Order of 3B & A and 4B & A is not ideal for the comparison. Perhaps start with WT and arrange the graphs in the order of decreasing activation. 3. Better use TH than THD as an abbreviation, to avoid phrases such as "F1 THD domain". In this study, Gingras, Lagarrigue et al identified an additional Rap1 binding site in Talin-1 (in the F1 domain; in addition to the previously described binding site in F0) and have convincingly demonstrate that this second Rap1 binding site is critical for Rap1 induced integrin activity in CHO cells expressing the platelet integrin alphaIIBbeta3 as a model system. This reviewer is not expert enough to thoroughly assess the quality of the in vitro binding assays NMR / biochemistry which constitute a large part of the present study. Therefore the comments below are mostly focused on the cell biology. That said the biochemistry data appear to be of very high quality and seem very convincing.
The authors clearly demonstrate that Rap1 binds to Talin F1 (to at least a very similar extend than to F0) and that disruption of this binding interferes with integrin activation when both CA-Rap1 and Talin head are over-expressed. The main limitation of this study is that it is currently very difficult to appreciate the contribution of this pathway to integrin activation, integrin biology or cellular functions in general. All the functional experiments are conducted with the CHO-model cell line and are restricted to integrin activity FACS assays. While the biochemical data are strongly supportive of the identification of a new talin-Rap1 interaction that is a key step in integrin activation it would be important for publication in a cell biological journal such as JCB to investigate the cell biological relevance of this interaction in other integrin regulated processes too.
In the cell type used by the authors CA-RAP1 alone appears do be completely unable to activate integrins. Could the authors provide a rational for this? Is there no endogenous talin in these cells ?
Similarly, in presence of an over-expressed talin-head construct (able to bind Rap1), CA-Rap1 appears to further increase integrin activity only very weakly (around 20% in Fig3B, or NS in Fig1 D) . This is a surprising results if Rap1 activation (an binding to talin) is the main regulator of integrin activity in these cells.
Other small GTPases of the RAS family have the potential to activate integrin. Would for instance R-Ras be able to also directly bind to talin F1 in the site identified here and modulate integrin activity ?
How "efficient" is the direct binding pathway in integrin activation compared to the classical Rap1-RIAM-Talin pathway previously described ?
The authors indicate that this pathway may be especially important in platelets where RIAM is missing. Could the importance of this pathway be tested in platelets ?
All the experiments performed here were done in cells kept suspension. Does the direct binding of Rap1 to talin F1 modulate integrin activity in spread cells ? Does it modulate integrin functions such as cell spreading or cell migration ?
Minor comments:
-Performing the integrin activity in presence or absence of manganese (to artificially maximize integrin activity) would help the reader to better appreciate the scale of the increased activity observed.
-In figure 1D , the authors should include the integrin activity induced by wt Talin head.
-It would be beneficial to present the integrin activation data in such a way that it would be easier for the reader to see the differences. For instance by displaying the EGFP CTRL first, then the WT THD then the mutants. The authors should also avoid the use of a bar chart which doesn't allow the reader to appreciate the spread of the data (ie single data points could be displayed on top of the bar chart). Finally the authors should perform statistical test to validate the difference observed between the various THD mutants (mock transfected, black bars).
-It would be beneficial to keep the cell line nomenclature consistent throughout the text. Sometime CHO cells is used, sometime A5, sometime both.
Reviewer #3 (Comments to the Authors (Required)):
The manuscript entitled « A Rap1 binding site and lipid-dependent helix in talin F1 domain cooperate in integrin activation » by Gingras et al. aims at clarifying the role of Rap1 in integrin activation through talin binding. Although the role of Rap1 in integrin activation has been clearly demonstrated the molecular mechanism is still elusive (Zhu et al. Nat Comm, 2017 , La Fuente Dev cell, 2004 . is The work is mainly based on NMR spectroscopy and aaiibb3 integrin activation assay. They showed that the integrin activator Rap1 is interacting with the F1 domain of talin. Thereby, they identified a novel Rap1 binding site on talin with similar affinity to the previously reported Rap1 binding site located on talin F0 domain (Lagarrigue et al. Blood adv. 2018 , Zhu et al. Nat Comm 2017 .
Interestingly, the capacity of the talin head domain to activate αIIbβ3 integrin was greatly reduced in talin F1 domain mutant that affects Rap1 interaction. Next, they analyzed the potential role of a loop located within the F1 talin domain that was previously reported to be required for integrin activation and membrane binding (Goult et al. EMBOJ, 2010) . They could show that removing this loop prevents integrin activation at a similar level when compared to Rap1 F1 defective mutant, thereby showing that Rap1 integrin activation relies on this F1 loop.
The authors present an interesting model in which Rap1 would favor talin/plasma membrane interaction that is primarily mediated through the positively charge loop within the F1 domain. This work definitely adds important information regarding the integrin activation mechanism. They also proposed an explanation for the lack of integrin activation defect observed in the F0 talin domain mutant (Lagarrigue et al. Blood Adv. 2018). Although the proposed mechanism is attractive additional evidences should be added to strengthen the manuscript and support their conclusions. Indeed, Rap1 still might be involved in different ways to explain their observations: lipid composition modification (via recruitment of lipid phosphatase/kinase), talin conformation changes... Therefore, additional biological evidences would further support their findings and the cooperative role of Rap1 in recruiting talin at the plasma membrane.
Major points :
-The interaction between talin head domain (or isolated F0/F1 domain) and Rap1 is only demonstrated through NMR spectroscopy. Additional methods should be used such as immunoprecipation using truncated proteins but also full-length ones.
-They provide evidences that both F0 and F1 domain appears to interact with Rap1 and with similar affinity. Thus it is still puzzling to me why the integrin activation defect was only observed when the F1 domain was mutated. Indeed, if Rap1 is required for increasing the talin docking to the plasma membrane why the F0 domain not doing a similar job? Please explain.
-Most of the work is based on truncated talin, it would increase the biological significance of the work if corresponding mutations are also analyzed using full-length proteins. Indeed, truncated protein might behave in a different way from the full-length form. Integrin activation as well as talin subcellular localization (ideally in a talin deficient background to avoid talin dimerization with endogenous talin) should be addressed.
-The authors propose that Rap1 cooperate with the F1 loop to dock talin head domain at the membrane. However this is poorly experimentally supported. Indeed, removing the talin F1 loop results in a similar integrin activation defect when compare to a mutant that targets both the loop and the talin F1 Rap1 (Fig 4B) . Similarly, expression of activated Rap1 or Rap1GAP1 did not significantly affect integrin activation ( Fig 4B) in cells expressing talin mutant lacking the F1 loop. This is clearly suggestive that Rap1 dependent integrin activation required the talin F1 loop but still cooperativity is not clearly demonstrated. The cooperative role of Rap1 binding sites (located in F0 and F1) and the F1 domain loop in regulating talin/lipid interaction should be more carefully analyzed using liposomes and purified membranes. Is the addition of a lipid anchor on talin THD would bypass the requirement of Rap-1 interaction? Is Rap1 inducing a conformation change in F1 domain to mediate a talin F1 loop/lipid interaction?
1st Revision -Authors' Response to Reviewers: February 11, 2019
Point by Point Responses

Reviewer #1
Not long ago Rap-dependent integrin activation was thought to be mediated solely by adaptor protein RIAM that interact with both talin and Rap1. However, some cell types, such as platelets, have very low level of RIAM and mouse models with RIAM KD did not show impaired integrin activation. This lead to further investigations that showed direct contribution of talin-Rap1 interaction into the integrin activation, attributed by Zhu ea (2018) to the talin F0 head domain. However, when the authors of this manuscript introduced the mutation into F0 that disrupts the interaction with Rap1, the activation of integrin was hardly affected (Lagarrigue et.al, 2018) , suggesting that F0 may not be the primary mediator of the Rap1-talin connection. This opened again the question of connection between Rap1 and talin in the absence of adaptor molecules. In the submitted manuscript the authors resolved this critical question by reporting a novel interaction between talin F1 and Rap1 that, in combination with the membrane-binding F1-loop, supports Rap1-dependent integrin activation. The manuscript is written clearly and supported by a combination on in vitro and cell data. The authors first demonstrate direct interaction between talin F1 and Rap1, and then use singleresidue mutations and domain deletions in A5 cells to relate the interaction to the integrin activation. Several points, however, need to be clarified.
1. The manuscript clearly contradicts the conclusion of Zhu ea (2018) that only F0 in the talin head binds Rap1. In that study, only the effect of F1F2 addition on 15N-Rap1 NMR signals was tested and no significant changes detected. However, the reverse experiment with using 15B-F1F2 was not conducted and no evidence of the correct folding of F1F2 presented, which limits the reliability of the conclusion. At the same time, the effect of Rap1 on the spectrum of 15N-F0 appears to much stronger than on 15N-F1 reported here. Zhu ea (2018) describe extensive broadening and significant shift changes in a number of resonances at 50 mM 15NF1 to 125 mM of Rap1, while Fig 2C of this manuscript shows much small changes at much larger excess of Rap1 (700mM), and no broadening of signals mentioned. Considering the importance of this evidence of the interaction, the changes in the spectra need to be presented in more detail.
(i) Summarise the chemical shift changes as a plot against the residue number and show the mapping of the significant changes on the F1 structure. Response: We added the plot in supplementary figure 2A for the residues that we could assign with confidence using the previously published NMR assignment from Goult et al., 2009 . We also mapped the significant changes on the F1 structure in Fig. S2 B, which makes clear that the binding is localized to a small surface, more specifically the beta2 strand of the F1 domain.
(ii) Show the changes of the side-chain Arg signals. Considering the predicted salt-bridges of the complex, large spectral changes are expected in these signals. The R118 signal should be possible to assign using R118E mutant. These data will also provide support for the formation of the salt bridges. Response: We agree with the reviewer that the side chain of Arg118 would be informative; however, the side-chain Arg118 was not assigned by Goult et al., 2009 and we also did not observe its signal at 1.5 mM talin F1. Furthermore, we did not observe any peaks disappearing in the Arginine side-chain region of the spectra in a full-sweep experiment with the R118E mutant, suggesting that its signal is not readily detected.
2. The binding constant has been estimated from extremely small shift changes of K89 and D94 (Fig2D & E) , which makes it highly unreliable. The spectra show larger shift changes, that, surprisingly, were not used, such as T96 and unmarked signal in the middle of the spectrum. Considering the small spectral differences, the authors should show the fitting of all the significant shift changes used and report individual Kds in the supplementary, and the largest in the main figure. Signals used in the Kd determination should be labeled on the spectrum. Response: The binding constant we reported was measured using several residues, as mentioned in the text. K89 and D94 are only examples that were shown in Fig. 1D 3. Model of the complex has to be presented to show complementary of the surfaces and formation of salt-bridges. Authors should consider HADDOCK as an independent way of generating the model of the complex based on the chemical shift mapping. Response: Fig. 2 (Fig. S2 B) is in the region where RA domains bind Rap1, therefore we think that a simple superimposition with the complex structure of F0-Rap1 would be both sufficient and justified.
4. Data on the WT needs to be presented in Fig.1D and compared to other fragments. Response: We have included data on THD in Fig. 1 D, which is now Fig. 1 (Plak et al. BMC Cell Biol 2016; Zhu et al. Nat Commun 2017; Lagarrigue et al. Blood Adv 2018; Bromberger et al. Blood 2018; Camp et al. J Cell Sci 2018) . Here, we report that a loss of function mutation of the F1 domain has a more dramatic effect in the integrin activation assay and in focal adhesion recruitment than that of F0 domain. We have included a more informative discussion in the last paragraph of the manuscript.
Minor points
1. Fig1A would be better shown as 3 separate spectra. Authors can consider including spectrum of 15N-Rap1 in the presence of F1-F3, which will further support their arguments. While R35E mutation reduces the affinity significantly, the residual binding might still be significant to cause broadening. Response: We made the figure using individual spectra (no overlays) 
Reviewer #2
In this study, Gingras, Lagarrigue et al identified an additional Rap1 binding site in Talin-1 (in the F1 domain; in addition to the previously described binding site in F0) and have convincingly demonstrate that this second Rap1 binding site is critical for Rap1 induced integrin activity in CHO cells expressing the platelet integrin alphaIIBbeta3 as a model system. This reviewer is not expert enough to thoroughly assess the quality of the in vitro binding assays NMR / biochemistry which constitute a large part of the present study. Therefore the comments below are mostly focused on the cell biology. That said the biochemistry data appear to be of very high quality and seem very convincing.
The authors clearly demonstrate that Rap1 binds to Talin F1 (to at least a very similar extend than to F0) and that disruption of this binding interferes with integrin activation when both CA-Rap1 and Talin head are over-expressed. The main limitation of this study is that it is currently very difficult to appreciate the contribution of this pathway to integrin activation, integrin biology or cellular functions in general. All the functional experiments are conducted with the CHO-model cell line and are restricted to integrin activity FACS assays. While the biochemical data are strongly supportive of the identification of a new talin-Rap1 interaction that is a key step in integrin activation it would be important for publication in a cell biological journal such as JCB to investigate the cell biological relevance of this interaction in other integrin regulated processes too. (Fig.S3D) and that the F1-Rap1 interaction are involved in focal adhesion recruitment (Fig.5A, 
Response: We thank the reviewer for constructive comments. In this JCB Report, our data show that Rap1 binding to talin1 F1 is a major regulator of integrin activation, which is an important component of integrin-dependent contributions to functions such as cell adhesion, cell migration, extracellular matrix assembly, leukocyte trafficking, and development. We have now extended our findings with the talin head domain to show that a similar principle applies to full length talin's effect on integrin activation
B ). Our combined structural and cell biological studies will enable future research to analyze the role of each of talin's Rap1 binding sites in the integrin activation-dependent cellular functions enumerated above.
We have previously reported that A5 cells express low levels of endogenous talin1 in comparison to platelets (Han et al. Current Biology 2006) and that expression of dominantactive Rap1A(G12V) leads to the activation of only αIIbβ3 in cells that had been cotransfected with talin1. These results indicate that low level of endogenous talin1 expression in A5 cells limits Rap1-dependent activation of αIIbβ3.
Similarly, in presence of an over-expressed talin-head construct (able to bind Rap1), CARap1 appears to further increase integrin activity only very weakly (around 20% in Fig3B, or NS in Fig1 D) . This is a surprising results if Rap1 activation (an binding to talin) is the main regulator of integrin activity in these cells.
Response: We assessed integrin αIIbβ3 activation in cells that are in suspension. Detachment of adherent cells is a potent activator of Rap1 GTPases. Thus, endogenous Rap1 activity is increased in response to the experimental conditions; thereby reducing the effect of exogenous constitutively activated Rap1 on THD-dependent integrin activation. We consider that the most important findings are that inhibition of Rap1 activity with Rap1-GAP1, suppresses activation by THD or by THD(R35E) by ~50%. In sharp contrast, a similar, reduced, level of activation is induced by THD(R118E) in the presence or absence of Rap1GAP1.
Other small GTPases of the RAS family have the potential to activate integrin. Would for instance R-Ras be able to also directly bind to talin F1 in the site identified here and modulate integrin activity 
Minor comments:
-Performing the integrin activity in presence or absence of manganese (to artificially maximize integrin activity) would help the reader to better appreciate the scale of the increased activity observed. Fig. S1 A. We observed that transfection of THD induces integrin activation similar to addition of manganese.
Response: We have included comparison of integrin activity in response to transfection of constructs encoding THD and addition of manganese. Data are presented in
-In figure 1D , the authors should include the integrin activity induced by wt Talin head. Fig. 1 D, which is now Fig. 1 -It would be beneficial to present the integrin activation data in such a way that it would be easier for the reader to see the differences. For instance by displaying the EGFP CTRL first, then the WT THD then the mutants. The authors should also avoid the use of a bar chart which doesn't allow the reader to appreciate the spread of the data (ie single data points could be displayed on top of the bar chart -It would be beneficial to keep the cell line nomenclature consistent throughout the text. Sometime CHO cells is used, sometime A5, sometime both.
Response: We have included data on THD in
Response: We have used "A5 cells" throughout the manuscript.
Reviewer #3
The manuscript entitled « A Rap1 binding site and lipid-dependent helix in talin F1 domain cooperate in integrin activation » by Gingras et al. aims at clarifying the role of Rap1 in integrin activation through talin binding. Although the role of Rap1 in integrin activation has been clearly demonstrated the molecular mechanism is still elusive (Zhu et al. Nat Comm, 2017 , La Fuente Dev cell, 2004 ). The work is mainly based on NMR spectroscopy and aaiibb3 integrin activation assay. They showed that the integrin activator Rap1 is interacting with the F1 domain of talin. Thereby, they identified a novel Rap1 binding site on talin with similar affinity to the previously reported Interestingly, the capacity of the talin head domain to activate αIIbβ3 integrin was greatly reduced in talin F1 domain mutant that affects Rap1 interaction. Next, they analyzed the potential role of a loop located within the F1 talin domain that was previously reported to be required for integrin activation and membrane binding (Goult et al. EMBOJ, 2010) . They could show that removing this loop prevents integrin activation at a similar level when compared to Rap1 F1 defective mutant, thereby showing that Rap1 integrin activation relies on this F1 loop. Fig. 4 B and Fig. 5 (Fig.  4 
Response: This comparison was presented in
B. Please note that Fig. 5 B has been moved to Fig. S3 A. We observed that deletion of the loop in F1 THD reduces integrin activation to a similar level as the Rap1-binding defective THD(R118E) mutant
B). Furthermore, introducing mutations of the basic amino acids in F1 loop that mediate interaction with lipids in THD(3EL) leads to a stronger inhibition of integrin activation, which we ascribe to electrostatic repulsion from the negatively charged lipids.
The authors present an interesting model in which Rap1 would favor talin/plasma membrane interaction that is primarily mediated through the positively charge loop within the F1 domain. This work definitely adds important information regarding the integrin activation mechanism. They also proposed an explanation for the lack of integrin activation defect observed in the F0 talin domain mutant (Lagarrigue et al. Blood Adv. 2018) . Although the proposed mechanism is attractive additional evidences should be added to strengthen the manuscript and support their conclusions. Indeed, Rap1 still might be involved in different ways to explain their observations: lipid composition modification (via recruitment of lipid phosphatase/kinase), talin conformation changes... Therefore, additional biological evidences would further support their findings and the cooperative role of Rap1 in recruiting talin at the plasma membrane.
Response: We agree with the reviewer that Rap1 could affect integrin activation by other mechanisms than direct binding to talin or via RIAM and have added this important caveat to the Discussion
Major points :
-The interaction between talin head domain (or isolated F0/F1 domain) and Rap1 is only demonstrated through NMR spectroscopy. Additional methods should be used such as immunoprecipation using truncated proteins but also full-length ones. Response: Because of the low affinity of the interaction in solution (e.g.Zhu et al. Nat Commun. 2017; 8(1):1744) , it is difficult to examine the co-immunoprecipitation of Rap1with talin1. Importantly, our NMR data unambiguously show the much-reduced affinity of the Rap1b interaction with talin1 F1 (R118E) mutant.
-They provide evidences that both F0 and F1 domain appears to interact with Rap1 and with similar affinity. Thus it is still puzzling to me why the integrin activation defect was only observed when the F1 domain was mutated. Indeed, if Rap1 is required for increasing the talin docking to the plasma membrane why the F0 domain not doing a similar job? Please explain. Response: Our previous data and the work of others indicate that F0 (Plak et al. BMC Cell Biol 2016; Zhu et al. Nat Commun 2017; Lagarrigue et al. Blood Adv 2018; Bromberger et al. Blood 2018; Camp et al. J Cell Sci 2018) -Most of the work is based on truncated talin, it would increase the biological significance of the work if corresponding mutations are also analyzed using full-length proteins. Indeed, truncated protein might behave in a different way from the full-length form. Integrin activation as well as talin subcellular localization (ideally in a talin deficient background to avoid talin dimerization with endogenous talin) should be addressed.
Response: We thank the reviewer for this suggestion. We have measured integrin activation in A5 cells that have been transfected with constructs encoding wild-type or mutant fulllength talin1. We observed the effects of R118E mutation and deletion of the loop in F1
subdomain using full-length proteins on integrin activity are similar to those using THD. Data are presented in Fig. S3 D-E.
-The authors propose that Rap1 cooperate with the F1 loop to dock talin head domain at the membrane. However this is poorly experimentally supported. Indeed, removing the talin F1 loop results in a similar integrin activation defect when compare to a mutant that targets both the loop and the talin F1 Rap1 (Fig 4B) . Similarly, expression of activated Rap1 or Rap1GAP1 did not significantly affect integrin activation (Fig 4B) in cells expressing talin mutant lacking the F1 loop. This is clearly suggestive that Rap1 dependent integrin activation required the talin F1 loop but still cooperativity is not clearly demonstrated. The cooperative role of Rap1 binding sites (located in F0 and F1) Thank you for submitting your revised manuscript entitled "A Rap1 binding site and lipid-dependent helix in talin F1 domain promote integrin activation in tandem". We apologize for the delay in providing you with a decision. Your manuscript has now been seen by the three original reviewers and, as you will see from the reports below, reviewers #1 and 2 now support publication. Reviewer #3, however, continues to feel that more work is needed in order to assess the relative role of this Rap1 binding of the talin F1 domain (compared to the well-characterized binding to the F0 domain -particularly in light of recent publications). While we agree with the reviewer that this is an interesting avenue of exploration that would undoubtedly increase the impact of the study, given that the current manuscript is a Report (rather than a full Article) and given that the study already examines the functional relevance of this particular interaction, we do not feel that these points will need to be addressed with new experiments. Therefore, we would be happy to publish your paper in JCB pending final revisions necessary to meet our formatting guidelines (see details below).
Although we will not be requiring new experiments in the final revision, we hope that you can address reviewer#1's and #3's comments through changes to the figures and/or text, including perhaps speculating a bit more on the relative contribution of this Rap1-talin F1 domain interaction (vs. the F0 domain interaction) and discussing how your work fits in the context of the recent studies that the reviewer has cited (Blood. 2018 Dec 27; 132(26):2754 -2762 and J Cell Sci. 2018 131(24) . pii: jcs225144). Please be sure to provide a full point-by-point rebuttal to this reviewer's comments along with your final revised manuscript.
To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.
A. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://jcb.rupress.org/submissionguidelines#revised. **Submission of a paper that does not conform to JCB guidelines will delay the acceptance of your manuscript.** 1) Text limits: Character count for Reports is < 20,000, not including spaces. Count includes title page, abstract, introduction, results, discussion, acknowledgments, and figure legends. Count does not include materials and methods, references, tables, or supplemental legends. We realize that you are currently over this limit (and, as noted above, will need to add even more text) but we feel that truncating the text any further would limit your ability to convey the main message of your paper effectively so we will give you more space this time. However, please do try to be as concise as possible.
2) Figure formatting: Scale bars must be present on all microscopy images, including inset magnifications. Molecular weight or nucleic acid size markers must be included on all gel electrophoresis.
3) Statistical analysis: Error bars on graphic representations of numerical data must be clearly described in the figure legend. The number of independent data points (n) represented in a graph must be indicated in the legend. Statistical methods should be explained in full in the materials and methods. For figures presenting pooled data the statistical measure should be defined in the figure legends. Please also be sure to indicate the statistical tests used in each of your experiments (both in the figure legend itself and in a separate methods section) as well as the parameters of the test (for example, if you ran a t-test, please indicate if it was one-or two-sided, etc.). Also, since you used parametric tests in your study (e.g. t-tests, ANOVA, etc.), you should have first determined whether the data was normally distributed before selecting that test. In the stats section of the methods, please indicate how you tested for normality. If you did not test for normality, you must state something to the effect that "Data distribution was assumed to be normal but this was not formally tested." 4) Materials and methods: Should be comprehensive and not simply reference a previous publication for details on how an experiment was performed. Please provide full descriptions (at least in brief) in the text for readers who may not have access to referenced manuscripts. 5) Please be sure to provide the sequences for all of your primers/oligos and RNAi constructs in the materials and methods. You must also indicate in the methods the source, species, and catalog numbers (where appropriate) for all of your antibodies. 6) Microscope image acquisition: The following information must be provided about the acquisition and processing of images: a. Make and model of microscope b. Type, magnification, and numerical aperture of the objective lenses c. Temperature d. imaging medium e. Fluorochromes f. Camera make and model g. Acquisition software h. Any software used for image processing subsequent to data acquisition. Please include details and types of operations involved (e.g., type of deconvolution, 3D reconstitutions, surface or volume rendering, gamma adjustments, etc.). 7) References: There is no limit to the number of references cited in a manuscript. References should be cited parenthetically in the text by author and year of publication. Abbreviate the names of journals according to PubMed. 8) Supplemental materials: There are strict limits on the allowable amount of supplemental data. Reports may have up to 3 supplemental figures. You currently meet this limit but please bear it in mind when revising. Please also note that tables, like figures, should be provided as individual, editable files. A summary of all supplemental material should appear at the end of the Materials and methods section. 9) Conflict of interest statement: JCB requires inclusion of a statement in the acknowledgements regarding competing financial interests. If no competing financial interests exist, please include the following statement: "The authors declare no competing financial interests." If competing interests are declared, please follow your statement of these competing interests with the following statement: "The authors declare no further competing financial interests." 10) ORCID IDs: ORCID IDs are unique identifiers allowing researchers to create a record of their various scholarly contributions in a single place. At resubmission of your final files, please consider providing an ORCID ID for as many contributing authors as possible.
B. FINAL FILES:
Please upload the following materials to our online submission system. These items are required prior to acceptance. If you have any questions, contact JCB's Managing Editor, Lindsey Hollander (lhollander@rockefeller.edu).
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure and video files: See our detailed guidelines for preparing your productionready images, http://jcb.rupress.org/fig-vid-guidelines.
--Cover images: If you have any striking images related to this story, we would be happy to consider them for inclusion on the journal cover. Submitted images may also be chosen for highlighting on the journal table of contents or JCB homepage carousel. Images should be uploaded as TIFF or EPS files and must be at least 300 dpi resolution. **It is JCB policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.** **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements before choosing the appropriate license.** Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.
